Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Pfizer Inc. agreed to pay over $59,746,277 to resolve allegations that its wholly owned subsidiary, Biohaven Pharmaceutical Holding Company Ltd., violated the Anti-Kickback Statute (AKS ...

Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that the subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), knowingly submitted or caused false ...

California Attorney General Bonta announced a settlement against Pfizer (PFE)-owned Biohaven Pharmaceutical “for submitting false claims to the Medicaid program and other government healthcare ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

The $59,746,277 settlement resolves a federal court case that Connecticut and 37 other states and Puerto Rico had joined against Biohaven Pharmaceutical Holding Company Ltd., a Pfizer-owned local ...